What is PTC Therapeutics's sephience — revenue?

PTC Therapeutics (PTCT) reported sephience — revenue of $124.55M in Q1 2026.

What does sephience — revenue mean?

This metric represents the total gross revenue generated from the Sephience product line or service segment, excluding any sales-related taxes collected on behalf of government authorities. It serves as a primary indicator of the market adoption and commercial performance of this specific therapeutic offering within the company's portfolio. Tracking this figure allows investors to assess the revenue contribution and growth trajectory of the Sephience segment relative to the company's overall biopharmaceutical operations.

PTC Therapeutics (PTCT) Sephience — Revenue

Screener

Other product segments

Translarna1

$235.3M—

Translarna

$58.98M—

Emflaza

$21.48M—

Other Products

$10.97M—

Upstaza And Kebilidi

$9.59M—

Similar metrics at other companies

HRO

HROWOther Revenues — Revenue

$73K-15.1%

ORCLCloud Revenues — Revenue

$9.91B+47.1%

ORCLSoftware Revenues — Revenue

$6.82B-2.1%

OWLPerformance revenues — Revenue

$6.07M-3.9%

EAT

EATFranchise revenues — Revenue

$14.7M+21.5%

CNKOther Revenues — Revenue

$113.1M+18.2%

Other financials

Income statement

See full

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

See full

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

See full

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

See full

Market cap$5.78B+41.9%

Enterprise value$5.34B+54.9%

P/E7.1×—

P/S7×+4.7×

Profitability

See full

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

See full

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.

Filed: May 7, 2026, 4:32 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001070081-26-000012

(in thousands)	Three Months ended March 31, 2026 / United States	Three Months ended March 31, 2026 / International	Three Months ended March 31, 2026 / Total	Three Months ended March 31, 2025 / United States	Three Months ended March 31, 2025 / International	Three Months ended March 31, 2025 / Total
Sephience	$112,040	12,511	$124,551	—	—	—
Translarna	—	58,976	58,976	—	86,154	86,154
Emflaza	21,478	—	21,478	47,789	—	47,789
Upstaza/Kebilidi	2,998	6,596	9,594	—	8,659	8,659
All other products	—	10,974	10,974	—	10,824	10,824
Total net product revenue	$$136,516	$89,057	$225,573	$47,789	$105,637	153,426

Item 1. Financial Statements (unaudited)

FAQ

What is PTC Therapeutics's sephience — revenue?: PTC Therapeutics (PTCT) reported sephience — revenue of $124.55M in Q1 2026.
What does sephience — revenue mean?: This metric represents the total gross revenue generated from the Sephience product line or service segment, excluding any sales-related taxes collected on behalf of government authorities. It serves as a primary indicator of the market adoption and commercial performance of this specific therapeutic offering within the company's portfolio. Tracking this figure allows investors to assess the revenue contribution and growth trajectory of the Sephience segment relative to the company's overall biopharmaceutical operations.